BofA Securities Maintains Hims & Hers Health(HIMS.US) With Sell Rating, Maintains Target Price $18
Hims & Hers up 18% Amid Optimism for Compounders With Makary FDA Pick
Unusual Options Activity: SPOT, MOD and Others Attract Market Bets, SPOT V/OI Ratio Reaches 90.4
Hims & Hers Health Gain on Potential FDA Leadership Ties
BridgeBio Pharma, Rigetti Computing, Bath & Body Works And Other Big Stocks Moving Higher On Monday
Applied Digital And Hims & Hers Health Are Among Top 9 Mid-Cap Gainers Last Week (Nov 18-Nov 22): Are The Others In Your Portfolio?
